Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes

Diabetologia. 2004 Dec;47(12):2208-14. doi: 10.1007/s00125-004-1591-4. Epub 2004 Dec 15.

Abstract

Aims/hypotheses: We examined the effects of lipase inhibition with orlistat on (i) gastric emptying of, and (ii) the glycaemic, glucagon-like peptide-1 (GLP-1) and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetic patients.

Methods: Eight type 2 diabetic patients, who were aged 62 years (median range: 49-68 years) and managed by diet alone, consumed a meal containing 65 g powdered potato, 20 g glucose reconstituted with 200 ml water (labelled with 20 MBq (99m)Tc-sulphur-colloid) and 45 g margarine. They did this on two separate occasions, with and without 120 mg orlistat, and while in the seated position with their back against a gamma camera. Venous blood samples for measurement of blood glucose, plasma insulin and GLP-1 were obtained immediately before the meal and at regular intervals afterwards. Blood pressure (systolic and diastolic) and heart rate were measured using an automated device.

Results: Gastric emptying of the meal was faster after orlistat than without orlistat (50% emptying time [mean +/- SEM], 61+/-8 min vs 98+/-5 min; p=0.0001). In the first 60 min after the meal blood glucose (p=0.001) and plasma insulin (p=0.01) concentrations were higher in patients who had taken orlistat; between 60 and 180 min plasma GLP-1 (p=0.02) concentrations were lower after orlistat than without orlistat. Between 0 and 30 min systolic blood pressure (p=0.003) was lower, and heart rate (p=0.03) greater in subjects who had taken orlistat than in those who had not.

Conclusions/interpretation: Inhibition of fat digestion by orlistat may-as a result of more rapid gastric emptying-exacerbate postprandial glycaemia and the postprandial fall in blood pressure in patients with type 2 diabetes after ingestion of meals containing fat and carbohydrate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism*
  • Blood Pressure / drug effects*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Dietary Carbohydrates / pharmacology*
  • Dietary Fats / pharmacology*
  • Enzyme Inhibitors / pharmacology
  • Female
  • Gastric Emptying / drug effects
  • Gastric Emptying / physiology*
  • Glucagon / blood*
  • Glucagon-Like Peptide 1
  • Heart Rate / drug effects*
  • Humans
  • Insulin / blood
  • Insulin / metabolism*
  • Insulin Secretion
  • Lactones / pharmacology*
  • Lipase / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Orlistat
  • Peptide Fragments / blood*
  • Protein Precursors / blood*

Substances

  • Blood Glucose
  • Dietary Carbohydrates
  • Dietary Fats
  • Enzyme Inhibitors
  • Insulin
  • Lactones
  • Peptide Fragments
  • Protein Precursors
  • Glucagon-Like Peptide 1
  • Glucagon
  • Orlistat
  • Lipase